ECEESPE2025 Poster Presentations Pituitary, Neuroendocrinology and Puberty (162 abstracts)
Soluble alpha Klotho concentrations in patients with pituitary adenomas
Júnia R.O.L. Schweizer 1 , Katharina Schilbach 1 , Frederick Vogel 1 , Isabel Stüfchen 1 , Friederike Völter 2 , Elisabeth Nowak 1 , Anica Pauline Gagliardo 1 , Stephanie Zopp 1 , Michael Haenelt 1 , Sylvère Störmann 1 , Jochen Schopohl 1 , Antonio Ribeiro de Oliveira Jr 3 , Juliana Drummond 4 , Martin Reincke 1 & Martin Bidlingmaier 1
1LMU Klinikum; Med. Klinik und Poliklinik IV/Endokrinologie, Munich, Germany; 2LMU Klinikum; Med. Klinik und Poliklinik IV/Nukelarmedizin/Endokrinologie, Munich, Germany; 3Crinetics Pharmaceuticals, Boston, United States; 4Federal Institution of Minas Gerais (UFMG), Endocrinology, Belo Horizonte, Brazil
JOINT860
Background: Alpha klotho is mainly expressed in the kidney but also in other organs, such as the pituitary gland. Soluble alpha klotho (sαKL) is a circulating protein that has been linked to endocrine functions. We previously showed high sαKL concentrations in active acromegaly. However, little is known about sαKL in pituitary adenomas beyond acromegaly. ObjectiveTo evaluate sαKL concentrations in patients with different types of pituitary adenomas.
Methods: We used an ELISA (IBL, Hamburg, Germany) to measure sαKL in patients prior to surgery for Cushing´s disease (n = 21, 6 males), prolactinoma (n = 44, 13 males), or non-functioning pituitary adenomas (NFPA, n = 9, 3 males), and compared concentrations to those seen in patients with active acromegaly (n = 29, 9 males). We also compared concentrations (mean [interquartile]) of sαKL to the classical biomarkers in acromegaly (IGF-I and IGFBP3). ResultsSαKL concentrations (pg/ml) were significantly higher in patients with acromegaly (Acro.: 5109 [2859-10232]) compared to all other groups (Cushing (Cush.: 728 [593-982], Prolactinoma (Prol.: 922 [786-1298], NFPA (922 [782-1111]; (Acro. vs. Cush. and Prol., P < 0.0001 for both comparisons and Acro. vs. NFPA, P = 0.0003). As expected, IGF-I and IGFBP3 were significantly higher in patients with acromegaly (753.9 [485.3-938.3], 6388 [5506-7354]) compared to patients with other pituitary adenomas (Cush.: 175.3 [110.4-228.8), 3212 [2501-3835], Prol.: 163.0 [134.0-201.5], 3896 [3433-4279], NFPA: 120.0 [104.5-174.0]), 3426 (3013-3759), Acro. vs. Cush., Prol. and NFPA, P < 0.0001 for all comparisons). Concentrations of sαKL, IGF-I and IGFBP3 did not differ significantly between patients with Cushing’s disease, prolactinoma and NFPA (P >0.05 for all comparisons). SαKL significantly correlated with IGF-I and IGFBP3 concentrations in patients with acromegaly (rs=0.66, P = 0.0001 and rs=0.43, P = 0.02, respectively), while there was no correlation with IGF-I or IGFBP3 in patients with other pituitary adenomas (P >0.05 for all). DiscussionOur study shows that in contrast to patients with acromegaly, sαKL is not grossly elevated in other pituitary adenomas. This supports the idea that sαKL concentrations are associated with high GH and/or IGF-I concentrations whereas influences of other hormone active or inactive pituitary adenomas itself might have, if any, a minor influence on sαKL concentrations.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more